This database contains 211 studies, archived under the term: "Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime"
Click here to filter this large number of results.
Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy
Modrego, P. J.,
Fayed, N.,
Errea, J. M.,
Rios, C.,
Pina, M. A.,
Sarasa, M.
Background and Purpose: To compare memantine with the most prescribed cholinesterase inhibitor (donepezil) from a clinical viewpoint when administered in early phases of Alzheimer disease (AD), and to find out whether memantine may produce changes in brain metabolite concentrations in comparison with donepezil.; Methods: In this comparative rater-blinded parallel group randomized trial we recruited a […]
Effect of cholinergic stimulation in early Alzheimer’s disease – functional imaging during a recognition memory task
Miettinen, Pekka S.,
Pihlajamäki, Maija,
Jauhiainen, Anne M.,
Tarkka, Ina M.,
Gröhn, Heidi,
Niskanen, Eini,
Hänninen, Tuomo,
Vanninen, Ritva,
Soininen, Hilkka
Treatment of Alzheimer’s disease (AD) with acetylcholinesterase inhibitors (AChEI) enhances cholinergic activity and alleviates clinical symptoms. In the present functional magnetic resonance imaging (fMRI) study, we investigated the effect of the AChEI rivastigmine on cognitive function and brain activation patterns during a face recognition memory task. Twenty patients with newly-diagnosed mild AD were administered a […]
A phase II trial of tideglusib in Alzheimer’s disease
Lovestone, Simon,
Boadab, Mercè,
Dubois, Bruno,
Hüll, Michael,
Rinne, Juha O.,
Huppertz, Hans-Jürgen,
Calero, Miguel,
Andrés, María V.,
Gómez-Carrillo, Belén,
Leon, Teresa,
del Seri, Teodoro
Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer’s disease (AD). Objective: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. Methods: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14–26) AD patients on cholinesterase inhibitor and/or memantine treatment […]
Memantine improves goal attainment and reduces caregiver burden in Parkinson’s disease with dementia
Objective: Memantine, an uncompetitive antagonist of N‐methyl‐D‐aspartate receptors, may have a role in managing symptoms associated with dementia in Parkinson’s disease (PDD), although its role in improving patient‐reported outcomes (PROs) has not been extensively investigated. PROs may be more sensitive than standard psychometric measures for detecting change in complex conditions such as PDD. The aim […]
Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008
Lazzeroni, Laura C.,
Halbauer, Joshua D.,
Ashford, J. Wesson,
Noda, Art,
Hernandez, Beatriz,
Azor, Virgina,
Hozack, Nikki,
Hasson, Noelle,
Henderson, Victor W.,
Yesavage, Jerome A.,
Tinklenberg, Jared R.
Alzheimer’s disease (AD) shortens life-expectancy, but the effects of pharmacological treatments for this disorder on mortality have not been studied. We compared two commonly prescribed medications, donepezil and memantine, with respect to the length of survival of veterans presumed to have AD. The Computerized Medical Records System at the Veterans Affairs Palo Alto Health Care […]
A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia
Jay Cheol Kwon,,
Eung Gyu Kim,,
Jae Woo Kim,,
Oh Dae Kwon,,
Bong Goo Yoo,,
Hyon Ah Yi,,
Nack Cheon Choi,,
Seon Young Ahn,,
Byung Hwa Lee,,
Myong Jin Kang,,
Dae Seob Choi,
Objectives: To evaluate the efficacy and tolerability of donepezil in patients with Binswanger type subcortical vascular dementia.; Methods: Patients (n = 34, mean age = 71.8 + 7.12) with Binswanger type subcortical vascular dementia from 8 multicenter, according to clinical and neuroradiological working criteria, were selected to receive donepezil 5 mg/day (n = 2) or […]
Does an interdisciplinary network improve dementia care? Results from the IDemUck-study
Kohler, Leonore,
Meinke-Franze, Claudia,
Hein, Jurgen,
Fendrich, Konstanze,
Heymann, Romy,
Thyrian, Jochen,
Hoffmann, Wolfgang
Background: Most persons with dementia live at home and are treated in the primary care. However, the ambulatory health care system in Germany contains a lot of “interface problems” and is not optimized for the future challenges. Innovative concepts like regional networks in dementia care exist on a project level and need to be tested […]